Background: Cytomegalovirus(CMV) pneumonia is uncommon in hematologic malignancy patients and clinical feature has been unclear. Methods: The clinical features of 16 patients with hematologic malignancy who were diagnosed as CMV pneumonia from August 2008 to July 2014 were retrospectively analyzed. Results: 43% (7/16) patients were female and average age was 42.5. All patients were performed bronchoscopy at the time of diagnosis. CMV PCR titer from bronchial washing fluid ranged from 6.71 x 103 to 1.5 × 108 copies/ml, and mean value was 9.74 × 106 copies/ml. CMV culture from bronchial washing fluid was positive in 43% (7/16) patients. Cytology from bronchial washing fluid was consistent with CMV virus in 1 case and lung biopsy was done in 4 cases to confirm CMV pneumonia. 75% (12/16) patients with CMV pneumonia had coinfection (5 cases of bacteria, 3 of virus, 2 of pneumocystosis, 4 of aspergillosis, 1 of tuberculosis, 1 of non-tuberculosis mycobacteria, 1 of mycoplasma). 62% (10/16) patients had undergone hematopoietic stem cell transplantation and only 1 patient was in nadir state. All patients were treated with antiviral agent in CMV pneumonia patients. Ganciclovir was used as first line agent in 87% (14/16) patients and 4 patients had changed medication to foscarnet due to treatment failure or complication of ganciclovir. 12% (2/16) patients were treated with foscarnet as first line therapy. 25% (4/16) patients received CMV immunoglobulin. 28-day mortality was 50%. Conclusions: CMV pneumonia is one of the most fatal conditions rarely accompanied in hematologic patients. We analyzed clinical feature in hematologic malignant patients with CMV pneumonia including bronchoscopic findings, coinfection, treatment and prognosis.